Soligenix, Inc. — Q1 2012 Form 10-Q
Reporting period: Three months ended March 31, 2012; filed May 14, 2012. Soligenix is a development-stage biopharmaceutical company with BioTherapeutics and Vaccines/BioDefense segments. Revenue was primarily from NIH grants; the company reported no material product-sales revenue.
Financial results and liquidity
| Metric | Q1 2012 | Q1 2011 / prior date |
|---|---|---|
| Grant revenue | $647,418 | $808,005 |
| Gross profit | $90,847; 14.0% margin | $253,968; 31.4% margin |
| Research and development | $876,794 | $1,372,804 |
| General and administrative | $655,043 | $604,010 |
| Operating loss | $1,440,990 | $1,722,846 |
| Net loss / loss per share | $1,438,755 / $0.13 | $1,720,411 / $0.16 |
| Operating cash used | $675,535 | $1,675,547 |
| Cash and cash equivalents | $5,321,133 | $5,996,668 at Dec. 31, 2011 |
| Working capital | $4,442,647 | $5,696,444 at Dec. 31, 2011 |
Cash declined $675,535 during the quarter. Total assets were $6.83 million and shareholders’ equity was $5.48 million at March 31. Current liabilities were $1.35 million; the balance sheet reports no debt. The company had an accumulated deficit of $119.56 million. No income tax provision was recorded because of losses and valuation allowances against deferred tax assets.
Material changes versus the prior period
- Revenue fell 20%, primarily reflecting lower NIH grant revenue. Gross profit decreased 64%, in part because prior-year gross profit included salary-cost reimbursement without corresponding current-period costs.
- R&D expense fell 36%, mainly following discontinuation of the confirmatory orBec Phase 3 trial for acute GI GVHD. G&A increased 8%, including higher salary allocation to administration as fewer programs were specifically identifiable as R&D.
- Net loss narrowed 16%. Operating cash use decreased 60%, which management attributed primarily to ending the pivotal orBec trial.
- The company completed a 1-for-20 reverse stock split on February 1, 2012; reported share and per-share data reflect the split.
Outlook, risks and notable items
- Management estimated existing cash would fund anticipated working capital and capital expenditures into the second quarter of 2013, relying on current outflows, grant proceeds, cost reductions, expected New Jersey tax-certificate proceeds, and timely collaboration milestone payments. This is not assured; management said it may seek additional equity financing.
- Approximately $3.8 million of active grant funding remained available for associated research programs into 2014. For the next 12 months, the company forecast about $3.3 million in R&D spending before grant reimbursements and approximately $2.2 million in grant revenue to offset R&D costs.
- The orBec confirmatory Phase 3 trial was stopped in September 2011 after interim results indicated it was highly unlikely to meet its efficacy endpoint; preliminary findings showed no significant difference from placebo on primary or specified secondary endpoints. Soligenix said it would terminate development for acute GI GVHD.
- Near-term plans included a planned Phase 2 program of oral BDP (SGX203) in pediatric Crohn’s disease, continued development of RiVax, VeloThrax and ThermoVax with government support, and evaluation of oral BDP in other GI indications. RiVax Phase 1B results were expected in 2012.
- Key risks include continued operating losses and need for funding, dependence on government grants and uncertain biodefense procurement, clinical and regulatory failure, reliance on partners and external manufacturers, and potential dilution or illiquidity of the OTC-traded stock. Management reported disclosure controls were effective and no material change in internal control over financial reporting during the quarter.
- Commitments included approximately $405,000 tied to licensing agreements, potentially payable upon milestones or commercialization, and total disclosed contractual obligations of $822,323 over 2012–2016. The company reported no current legal proceedings.
Most important facts for investors to verify
- Whether grant funding, expected tax-certificate proceeds, and any collaboration milestones are received on schedule—and whether cash runway remains consistent with management’s second-quarter 2013 estimate.
- Progress and funding for SGX203, RiVax, VeloThrax and ThermoVax, including the expected RiVax results and any subsequent clinical or grant developments.
- The status of the orBec collaboration with Sigma-Tau and the practical effect of ending the acute GI GVHD indication on milestone expectations and other oral BDP programs.
- Future financing needs and potential dilution, including the company’s outstanding options and warrants; reported weighted-average exercise prices were above the May 10, 2012 closing share price of $0.35.